Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
Pricewatch: A reader’s donation of spare virtual change to the Red Cross led to her unwittingly giving, over a period of several months, a sum she could not afford
Victor Stinga, the interim CFO of Revolut, said the fintech wants to launch mortgages and savings accounts as a rising number of European clients, including Romanian ones, are starting to see Revolut as a main banking account, an alternative to traditional banks or a service that is complementary to them.